Content
03/24/2025
Oakland, CA USA
Tempero Bio
completed $70 million Series B Round funding. Investors include
8VC (lead), Khosla Ventures.
About
Tempero Bio is a clinical-stage biopharmaceutical company committed to developing innovative treatments for substance use disorders—chronic, relapsing brain diseases with limited pharmacologic solutions. The company is dedicated to advancing science-driven therapies that redefine treatment paradigms. Tempero Bio is an Aditum Bio portfolio company.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
